Precision oncology specialist Guardant Health (GH 0.57%) was something of a stock market star on Tuesday.

"Guardant Health, Inc. (NASDAQ:GH) was a relative contributor in the first quarter following several positive announcements and solid fourth quarter earnings.

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from m ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360 ® Liquid test that greatly expand its biomarker identification ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi- ...

Guardant Health raises 2025 revenue guidance to $880-$890M amid strong oncology and screening growth Apr. 30, 2025 10:26 PM ET Guardant Health, Inc. (GH) Stock AI-Generated Earnings Calls Insights ...

Guardant Health, Inc., a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages ...

Guardant Health's Shield test receives FDA breakthrough status and NCCN guideline inclusion, with high accuracy shown in new ASCO and ECLIPSE study data.

Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped ...

Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped ...